Onyx Pharmaceuticals is developing innovative small molecule cancer treatments based on a molecular understanding of cancer. Our lead product is Nexavar® (sorafenib) tablets, a novel, oral multiple kinase inhibitor that targets proteins involved in both tumor cell proliferation and angiogenesis (the formation of new blood vessels to support cancer cell growth). This product is being developed and marketed in collaboration with Bayer HealthCare Pharmaceuticals.

Nexavar is approved in the U.S. (view press release) and the EU (view press release) for the treatment of patients with advanced kidney cancer. Additionally, Nexavar recently received approval in a second indication, liver cancer, in the U.S. (view press release) and in the EU (view press release). These approvals were based on clinical results demonstrating Nexavar's efficacy in significantly extending overall survival in patients with the most common form of liver cancer, hepatocellular carcinoma (HCC).

As a part of a broad development program, Nexavar is currently being evaluated in randomized trials in non-small cell lung cancer, breast cancer, melanoma and other tumor types. The agent is also being studied in multiple Phase 2 trials, as well as in several Phase 1b studies evaluating its use in combination with standard chemotherapies and other anticancer agents. In addition, we have a small molecule cell cycle inhibitor resulting from a collaboration with Pfizer that entered clinical testing in 2004.

By exploiting the genetic differences between cancer cells and normal cells, Onyx is focused on providing a new generation of improved cancer therapeutics.

Since our establishment in 1992, we have been guided by the vision of founder Frank McCormick, Ph.D., F.R.S., an internationally recognized scientist and currently Director of the University of California San Francisco Comprehensive Cancer Center and Cancer Research Institute. This vision, which is demonstrated by our slogan Changing the way cancer is treated™, has led to the discovery of proprietary compounds that target cancer cells while minimizing damage to normal cells.

Onyx common stock is traded on the Nasdaq Global Market under the symbol ONXX.